Klinická farmakologie a farmacie

KLINICKÁ FARMAKOLOGIE A FARMACIE / Klin Farmakol Farm 2020; 34(2): 63–69 / www.klinickafarmakologie.cz 68 PŘEHLEDOVÉ ČLÁNKY Vliv genetických a epigenetických faktorů jako kovariátů snášenlivosti a léčebné odpovědi na olanzapin v terapii psychotických onemocnění dictors of poor treatment response in patients with schizo phrenia treated with atypical antipsychotics. BMC Psychia try 2018; 18: 376. 8. Stahl SM. Stahl’s Essential Psychopharmacology Camb ridge University Press 2013: 608. 9. Citrome L, McEvoy JP, Todtenkopf MS, McDonnell D, Weiden PJ. A commentary on the efficacy of olanzapine for the treatment of schizophrenia: the past, present, and futu re. Neuropsychiatr Dis Treat 2019; 15: 2559–2569. 10. Cabaleiro T, Lopez‑Rodriguez R, Ochoa D, Roman M, No valbos J, Abad‑Santos F. Polymorphisms influencing olan zapine metabolism and adverse effects in healthy subjects. Human Psychopharmacology‑Clinical and Experimental 2013; 28: 205–214. 11. Chagraoui A, Thibaut F, Skiba M, Thuillez C, Bourin M. 5-HT2C receptors in psychiatric disorders: A review. Progre ss in Neuro‑Psychopharmacology & Biological Psychiatry 2016; 66: 120–135. 12. Perry PJ, Sanger T, Beasley C. Olanzapine plasma concen trations and clinical response in acutely ill schizophrenic pa tients. J Clin Psychopharmacol 1997; 17: 472–477. 13. Hiemke C, Bergemann N, Clement HW, Conca A, Deckert J, Domschke K, Eckermann G, et al. Consensus Guidelines for Therapeutic Drug Monitoring in Neuropsychopharmacology: Update 2017. Pharmacopsychiatry 2018, 51: e1. 14. Carrillo JA, Herraiz AG, Ramos SI, Gervasini G, Vizcaino S, Benitez J. Role of the smoking‑induced cytochrome P450 (CYP)1A2 and polymorphic CYP2D6 in steady‑state concen tration of olanzapine. Journal of Clinical Psychopharmaco logy 2003; 23: 119–127. 15. Bozikas VP, Papakosta M, Niopas L, Karavatos A, Mirtsou ‑Fidani V. Smoking impact on CYP1A2 activity in a group of patients with schizophrenia. European Neuropsychophar macology 2004; 14: 39–44. 16. Nozawa M, Ohnuma T, Matsubara Y, Sakai Y, Hatano T, Hanzawa R, Shibata N, et al. The relationship between the response of clinical symptoms and plasma olanzapine con centration, based on pharmacogenetics. Therapeutic Drug Monitoring 2008; 30: 35–40. 17. Bondolfi G, Morel F, Crettol SV, Rachid F, Baumann P, Eap CB. Increased clozapine plasma concentrations and side effects induced by smoking cessation in 2 CYP1A2 genoty ped patients. Therapeutic Drug Monitoring 2005; 27: 539–543. 18. Gaedigk A, Leeder S, Miller N, Hoffman M, Lee M, Phillips M, Pratt V, et al. Pharmacogene Variation Consortium (Phar mVar). ed. Children’s Mercy in Kansas City, USA: Pharmaco gene Variation Consortium (PharmVar) 2019. 19. Tay JK, Tan CH, Chong SA, Tan EC. Functional polymor phisms of the cytochrome P450 1A2 (CYP1A2) gene and pro longed QTc interval in schizophrenia. Prog Neuropsychophar macol Biol Psychiatry 2007; 31: 1297–1302. 20. Yasar U, Babaoglu MO, Balibey H, Cetin M, Lundgren S, Rane A, Bozkurt A. Association of the cytochrome P450 1A2*1 F polymorphism with clozapine response in schizo phrenic patients. Faseb Journal 2007; 21: A196-A196. 21. Czerwensky F, Leucht S, Steimer W. CYP1A2*1D and *1 F polymorphisms have a significant impact on olanzapine serum concentrations. Ther Drug Monit 2015; 37: 152–160. 22. Ghotbi R, Mannheimer B, Aklillu E, Suda A, Bertilsson L, Eliasson E, Osby U. Carriers of the UGT1A4 142 T>G gene va riant are predisposed to reduced olanzapine exposure--an impact similar to male gender or smoking in schizophrenic patients. Eur J Clin Pharmacol 2010; 66: 465–474. 23. Mao M, Skogh E, Scordo MG, Dahl ML. Interindividual vari ation in olanzapine concentration influenced by UGT1A4 L48V polymorphism in serumand upstreamFMOpolymorphisms in cerebrospinal fluid. J Clin Psychopharmacol 2012; 32: 287–289. 24. Bozina N, Kuzman MR, Medved V, Jovanovic N, Sertic J, Hotujac L. Associations between MDR1 gene polymorphisms and schizophrenia and therapeutic response to olanzapine in female schizophrenic patients. Journal of Psychiatric Re search 2008; 42: 89–97. 25. Rao VV, Dahlheimer JL, Bardgett ME, Snyder AZ, Finch RA, Sartorelli AC, Piwnica‑Worms D. Choroid plexus epithelial ex pression of MDR1 P glycoprotein and multidrug resistance ‑associated protein contribute to the blood‑cerebrospinal ‑fluid drug‑permeability barrier. Proc Natl Acad Sci U S A 1999; 96: 3900–3905. 26. Boulton DW, DeVane CL, Liston HL, Markowitz JS. In vit ro P‑glycoprotein affinity for atypical and conventional an tipsychotics. Life Sci 2002; 71: 163–169. 27. Tiwari AK, Sodani K, Dai CL, Ashby CR, Chen ZS, Chen ZS. Revisiting the ABCs of Multidrug Resistance in Cancer Che motherapy. Current Pharmaceutical Biotechnology 2011; 12: 570–594. 28. Fardel O, Lecureur V, Guillouzo A. The P‑glycoprotein mul tidrug transporter. General Pharmacology 1996; 27: 1283–1291 29. Schinkel AH, Wagenaar E, Mol CAAM, vanDeemter L. P ‑glycoprotein in the blood‑brain barrier of mice influences the brain penetration and pharmacological activity of many drugs. Journal of Clinical Investigation 1996; 97: 2517–2524. 30. Lankas GR, Wise LD, Cartwright ME, Pippert T, Umben hauer Dr. Placental P‑glycoprotein deficiency enhances sus ceptibility to chemically induced birth defects in mice. Re productive Toxicology 1998; 12: 457–463. 31. Lin YC, Ellingrod VL, Bishop JR, Miller DD. The relationship between P‑glycoprotein (PGP) polymorphisms and response to olanzapine treatment in schizophrenia. Therapeutic Drug Monitoring 2006; 28: 668–672. 32. Kuzman MR, Medved V, Bozina N, Grubisin J, Jovanovic N, Sertic J. Association study of MDR1 and 5-HT2C genetic polymorphisms and antipsychotic‑induced metabolic dis turbances in female patients with schizophrenia. Pharma cogenomics Journal 2011; 11: 35–44. 33. Jovanovic N, Bozina N, Lovric M, Medved V, Jakovljevic M, Peles AM. The role of CYP2D6 and ABCB1 pharmacogene tics in drug‑na < ve patients with first‑episode schizophrenia treated with risperidone. European Journal of Clinical Phar macology 2010; 66: 1109–1117. 34. al Mouaffak F, Oussama K, Picard V, Bonhomme‑Faivre L. Ultra‑Resistant Schizophrenia Is Not Associated With the Multidrug‑Resistant Transporter 1 (MDR1) Gene rs1045642 Variant. Journal of Clinical Psychopharmacology 2011; 31: 2. 35. Lee ST, Ryu S, Kim SR, KimMJ, Kim S, Kim JW, Lee SY, et al. Association study of 27 annotated genes for clozapine phar macogenetics: validation of preexisting studies and identifi cation of a new candidate gene, ABCB1, for treatment respon se. J Clin Psychopharmacol 2012; 32: 441–448. 36. Saiz‑Rodríguez M, Belmonte C, Román M, Ochoa D, Jiang ‑Zheng C, Koller D, Mejía G, et al. Effect of ABCB1 C3435T Po lymorphism on Pharmacokinetics of Antipsychotics and An tidepressants. Basic Clin Pharmacol Toxicol 2018; 123: 474–485. 37. Tovilla‑Zarate C, Vargas I, Hernandez S, Fresan A, Aguilar A, Escamilla R, Saracco R, et al. Association study between the MDR1 gene and clinical characteristics in schizophrenia. Re vista Brasileira De Psiquiatria 2014; 36: 227–232. 38. PanJ,HanJ,WuJ,HuangH,YuQ,ShengL.MDR1SingleNuc leotidePolymorphismG2677T/AandHaplotypeAreCorrelated withResponsetoDocetaxel‑CisplatinChemotherapy inPatients with Non‑Small‑Cell Lung Cancer. Respiration 2009; 78: 49–55. 39. Fernandes B, Steiner J, Berk M, Molendijk M, Gonzalez ‑Pinto A, Turck C, Nardin P, et al. Peripheral brain‑derived neurotrophic factor in schizophrenia and the role of antipsy chotics: meta‑analysis and implications. Molecular Psychiat ry 2015; 20: 1108–1119. 40. Můj případ – Je kyselina acetylsalicylová v každé tabletě stejná? Bulletin Sdružení praktických lékařů ČR 2015; 25: 57–58. 41. Huang E, Hettige NC, Zai G, Tomasi J, Huang J, Zai CC, Pi vac N, et al. BDNF Val66Met polymorphism and clinical re sponse to antipsychotic treatment in schizophrenia and schi zoaffective disorder patients: a meta‑analysis. Pharmacoge nomics J 2019; 19: 269–276. 42. Zai G, Zai C, Chowdhury N, Tiwari A, Souza R, Lieber man J, Meltzer H, et al. The role of brain‑derived neurotro phic factor (BDNF) gene variants in antipsychotic response and antipsychotic‑induced weight gain. Progress in Neuro ‑Psychopharmacology & Biological Psychiatry 2012; 39: 96–101. 43. Abdolmaleky HM, Faraone SV, Glatt SJ, Tsuang MT. Meta ‑analysis of association between the T102C polymorphism of the 5HT2a receptor gene and schizophrenia. Schizophre nia Research 2004; 67: 53–62. 44. Myers RL, Airey DC, Manier DH, Shelton RC, Sanders‑Bush E. Polymorphisms in the regulatory region of the human se rotonin 5-HT2A receptor gene (HTR2A) influence gene ex pression. Biological Psychiatry 2007; 61: 167–173. 45. Davies MA, Conley Y, Roth BL. Functional SNPs in Genes Encoding the 5-HT2A Receptor Modify the Affinity and Po tency of Several Atypical Antipsychotic Drugs. Biological Re search for Nursing 2011; 13: 55–60. 46. Gu L, Long JX, Yan Y, Chen Q, Pan RD, Xie XF, Mao XX, et al. HTR2A1438A/G polymorphism influences the risk of schi zophrenia but not bipolar disorder or major depressive di sorder: A meta‑analysis. Journal of Neuroscience Research 2013; 91: 623–633. 47. Joober R, Benkelfat C, Brisebois K, Toulouse A, Turecki G, Lal S, BloomD, et al. T102C polymorphism in the 5HT2A gene and schizophrenia: relation to phenotype and drug response variability. J Psychiatry Neurosci 1999; 24: 141–146. 48. Chen RYL, Sham P, Chen EYH, Li T, Cheung EFC, Hui TCK, Kwok CL, et al. No association between T102C polymor phism of serotonin-2 Areceptor gene and clinical phenoty pes of Chinese schizophrenic patients. Psychiatry Research 2001; 105: 175–185. 49. Hawi Z, Myakishev MV, Straub RE, ONeill A, Kendler KS, Wal sh D, Gill M. No association or linkage between the 5-HT2a/ T102C polymorphism and schizophrenia in Irish families. American Journal of Medical Genetics 1997; 74: 370–373. 50. Arranz MJ, Collier DA, Munro J, Sham P, Kirov G, Sodhi M, Roberts G, et al. Analysis of a structural polymorphism in the 5-HT2A receptor and clinical response to clozapine. Neuros cience Letters 1996; 217: 177–178. 51. Arranz MJ, Munro J, Birkett J, Bolonna A, Mancama D, Sod hi M, Lesch KP, et al. Pharmacogenetic prediction of clozapi ne response. Lancet 2000; 355: 1615–1616. 52. Saiz PA, Garcia‑Portilla MP, Arango C, Morales B, Alvarez V, Coto E, Fernandez JM, et al. Association study of seroto nin 2 Areceptor (5-HT2A) and serotonin transporter (5-HTT) gene polymorphisms with schizophrenia. Progress in neuro ‑psychopharmacology&biologicalpsychiatry2007;31:741–745. 53. Souza RP, de Luca V, Meltzer HY, Lieberman JA, Kennedy JL. Influence of serotonin 3 Aand 3 B receptor genes on clo zapine treatment response in schizophrenia. Pharmacoge netics and Genomics 2010; 20: 274–276. 54. McMahon F, Buervenich S, Charney D, Lipsky R, Rush A, Wilson A, Sorant A, et al. Variation in the gene encoding the serotonin 2 Areceptor is associated with outcome of antide pressant treatment. American Journal of Human Genetics 2006; 78: 804–814. 55. Laika B, Leucht S, Heres S, Schneider H, Steimer W. Phar macogenetics and olanzapine treatment: CYP1A2(star)1 F and serotonergic polymorphisms influence therapeutic outcome. Pharmacogenomics Journal 2010; 10: 20–29. 56. Li J, Hashimoto H, Meltzer HY. Association of Serotonin 2c Receptor Polymorphisms With Antipsychotic Drug Response in Schizophrenia. Front Psychiatry 2019; 10: 58. 57. Wallace TJ, Zai CC, Brandl EJ, Müller DJ. Role of 5-HT(2C) receptor gene variants in antipsychotic‑induced weight gain. Pharmgenomics Pers Med 2011; 4: 83–93. 58. Huang XF, Tan YY, Huang X, Wang Q. Effect of chronic tre atment with clozapine and haloperidol on 5-HT2A and 2C receptor mRNA expression in the rat brain. Neuroscience Re search 2007; 59: 314–321. 59. Padin JF, Rodriguez MA, Dominguez E, Dopeso‑Reyes IG, Buceta M, Cano E, Sotelo E, et al. Parallel regulation by olan zapine of the patterns of expression of 5-HT2A and D3 re ceptors in rat central nervous system and blood cells. Neu ropharmacology 2006; 51: 923–932. 60. Godlewska B, Olajossy‑Hilkesberger L, Ciwoniuk M, Ola jossy M, Marmurowska‑Michalowska H, Limon J, Landowski

Klinická farmakologie a farmacie – 2/2020